Correction: TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach
Tayebeh Cheraghi-shavi, Razieh Jalal, Zarrin Minuchehr, Frouzandeh Mahjoubi
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsColorectal Cancer Treatments and Studies · Genomics, phytochemicals, and oxidative stress · Tannin, Tannase and Anticancer Activities
Frouzandeh Mahjoubi is not included in the author byline. Frouzandeh Mahjoubi should be listed as the fourth author and is affiliated with Department of Medical Genetics, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran. The contributions of this author are as follows: Methodology, Supervision.
The correct citation is: Cheraghi-shavi T, Jalal R, Minuchehr Z, Mahjoubi F (2023) TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach. PLoS ONE 18(8): e0289535. https://doi.org/10.1371/journal.pone.0289535.
The reference list from the paper itself. Each links out to its DOI / PubMed record.